BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

Vaccines

SK bioscience Introduces New Partnership Model to Establish Regional Vaccine Hubs

SK bioscience shared a development history of the South Korea’s first COVID-19 vaccine at the Riyadh Global Medical Biotechnology Summit 2023 (RGBM...

January 27, 2023 | News

AstraZeneca Begins Tender Offer to Acquire CinCor Pharma, Inc.

On 9 January 2023, AstraZeneca announced that it had entered into a definitive agreement to acquire CinCor. Following the successful closing of the tender ...

January 23, 2023 | News

KBI Biopharma Announces Subcontract with Mapp Biopharmaceutical on Sudan ebolavirus Treatment

KBI Biopharma, Inc. (KBI), a JSR Life Sciences company, today announced it entered into a subcontract with Mapp Biopharmaceutical, Inc. (Mapp) for the cont...

January 23, 2023 | News

Novavax Nuvaxovid COVID-19 Vaccine Approved in South Korea as an Adult Booster

"We are pleased to collaborate with SK bioscience to offer our protein-based vaccine, Nuvaxovid, for use as a booster in adults regardless of previous vacc...

January 19, 2023 | News

ProBioGen’s Vaccine Production Cell Line AGE1.CR.pIX® Used for Clinical Production

Our valued customer Nouscom recently proclaimed that their sub-licensee, has initiated phase 1 clinical trials for VAC85135, a viral vector-based cancer va...

January 18, 2023 | News

SK bioscience's Zoster Vaccine Receives Biologics License Application Approval in Malaysia

The world-second developed shingles vaccine 'SKYZoster™' is approved by the National Pharmaceutical Regulatory Agency (NPRA) SK biosciences p...

January 10, 2023 | News

Novavax Announces Initiation of Phase 2 Trial for COVID-19-Influenza Combination and Stand-Alone Influenza Vaccine Candidates

The dose-confirming trial will evaluate the safety and effectiveness (immunogenicity) of different formulations of the CIC and influenza vaccine candidates...

January 02, 2023 | News

China to downgrade COVID-19 management to Class B

In a statement released late Monday, the National Health Commission (NHC) renamed the Chinese term for COVID-19 from "novel coronavirus pneumonia" to "nove...

December 28, 2022 | News

Everest Medicines Announces New mRNA Rabies Vaccine Program and Achievement of Preclinical Proof-of-Concept Milestone

Rabies program, as the first non-COVID19 vaccine developed with a specialized mRNA platform, highlights Everest's discovery capabilities Clinically valida...

December 15, 2022 | News

China further optimizes COVID-19 response with new measures

Local authorities across China have soon made specific policies to implement the 10 new prevention and control measures recently rolled out by th...

December 12, 2022 | News

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

Bivalent vaccine authorized as third 3-µg dose in the three-dose primary series Consistent COVID-19 hospitalization rates in this age group couple...

December 08, 2022 | News